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Tyrosine kinase inhibitors (TKIs) have emerged as a targeted therapy of interest for the treatment of systemic sclerosis (SSc).
Recently, several groups have performed pilot or “proof-of-concept” studies to determine the feasibility of this approach for the
treatment of the cutaneous and pulmonary manifestations of this multisystem disease. The conclusions drawn by these diﬀerent
studies have been conﬂicting, and some controversy has arisen as to whether tyrosine kinase inhibition is a treatment approach
worthy of continued study. This paper summarizes this research to date with emphasis on the challenges in interpreting proof-of-
concept studies in this patient group.
1.Introduction
Systemic sclerosis (SSc) is a heterogeneous, multisystem
disorder characterized by vasculopathy, ﬁbrosis, and autoim-
munityinthecontextofbothgeneticandenvironmentalfac-
tors [1]. Although the pathogenesis of SSc is not completely
understood, there is strong evidence for a central role of
abnormal signaling through the transforming growth factor
beta (TGFβ)p a t h w a y[ 2]. The intracellular tyrosine kinase
(TK) c-abl has been implicated in the downstream signaling
pathways of TGFβ [3]. There is additional evidence for ab-
normalities in the platelet-derived growth factor (PDGF)
axis, signaling through the receptor TK the PDGF receptor
(R), as contributory to the pathogenesis of SSc as well [4].
Because of the roles of these pathways, there has been
interest in evaluating the speciﬁc tyrosine kinase inhibitors
(TKIs) which are able to block c-abl and the PDGFR in
the treatment of SSc [5]. These include imatinib mesylate
(Gleevec; Novartis Pharmaceuticals; Basel, Switzerland),
dasatinib(Sprycel;BristolMyersSquibb;NewYork,NY),and
nilotinib (Tasigna; Novartis Pharmaceuticals) all of which
inhibit c-abl and the PDGFR with diﬀerent degrees of
potency[6].AllthreeofthesemedicationsareFDAapproved
for the treatment of chronic myelogenous leukemia (CML),
and imatinib is additionally FDA approved for the treatment
ofgastrointestinalstromaltumor(GIST)inadditiontoother
hematologic and oncologic conditions [7–10]. Each medica-
tion is additionally capable of inhibiting other kinases. For
example, imatinib inhibits c-kit, and dasatinib inhibits src
kinases. It is possible that some of these diﬀerent pathways
could prove to be of biologic interest in ﬁbrosing disorders.
Each of these TKIs also has slightly diﬀerent side eﬀect
proﬁles [11], which may also make one or another of them
favorable for the treatment of SSc.
Imatinib, nilotinib, and dasatinib have been shown in
in vitro models to decrease the TGF-β and PDGF-mediated
production of extracellular matrix proteins and to abrogate
skin thickening observed in mouse models of SSc [12, 13].
Imatinib has also shown antiﬁbrotic properties in preclinical
models of renal [14], hepatic [15], and pulmonary ﬁbrosis
[16]. Case reports of imatinib have shown promise to this
treatment approach [17–21]. To date there have been several
“proof-of-concept” (POC) approaches to determine the
safety and potential eﬃcacy of TKIs for dcSSc. The inclusion
criteria and dosing of the various investigations have varied
but the designs are similar as open-label and uncontrolled
investigations to assess safety, eﬃcacy, and eﬀect on potential
biomarkers of disease. The purpose of this paper is to review
these investigations to date with a discussion of the various
caveats that come into play with this type of study in SSc.2 International Journal of Rheumatology
It is our opinion that these POC approaches can have
great value in the search for improved treatment for this
group of patients. However, POC trials pose challenges in
study design and have important limitations to the conclu-
sions that can be drawn from them. These POC approaches
are appealing because they can utilize a smaller number of
patients andprovide insight into biologic eﬀect,initial safety,
and treatment eﬀect in vivo. They can be used as an initial
(but not deﬁnitive) test for clinical questions and are also an
opportunity to test hypotheses with respect to biologic eﬀect
of treatment and biomarkers in SSc. The term “proof of con-
cept” or “proof of principle” can hold several meanings. In
generalthetermreferstoanimalorhumanstudieswhichcan
provide evidence for or against a pharmacological or clinical
eﬀect. In industry-based drug development these POC trials
are used for investment or “go/no go” decisions [22].
Multiple aspects of SSc make it diﬃcult to ﬁt into this
“go/no go” mold. Firstly, SSc is a rare, heterogeneous, and
multisystemic disease. Clinical endpoints and study design
vary depending on whether the outcome of interest is cuta-
neous, pulmonary, vascular, or other. Patient recruitment is
diﬃcult because of the rarity of the condition, and the
natural history of the involvement of each organ system
is variable. Validated clinical endpoints exist for diﬀerent
outcomes, but some, for example, the modiﬁed Rodnan Skin
Score (mRSS), may be open to bias in an uncontrolled trial,
whereas others, for example, the forced vital capacity (FVC),
are more objective. Many diﬀerent biomarkers are under
investigation and some have been validated in small popu-
lations or under certain circumstances [23]. However, these
biomarkers have not yet been tested in clinical trials nor have
they been shown to be prognostic at this point in time (with
the exception of autoantibodies which have prognostic value
at baseline but have not been shown to change with clinical
status). The ability to deﬁne biomarkers has been further
frustrated by the lack of unequivocably eﬃcacious therapies
in this condition. POC trials provide an initial insight
into whether an agent seems to have acceptable safety and
tolerability in the target population and whether there is a
suggestion of eﬃcacy that would make a larger double-blind
randomized placebo-controlled trial worthwhile as well as
how to power such an endeavor.
The investigation of TKIs in SSc is a case study of these
issues.
1.1. Preclinical Studies Assessing Tyrosine Kinase Inhibitors for
the Treatment of Fibrosis. Distler et al. showed that the treat-
ment of cultured ﬁbroblasts from both SSc patients and
healthy controls with imatinib led to a dose-dependent
inhibition of the synthesis of collagen Ia1, collagen Ia2,
and ﬁbronectin-1 when the ﬁbroblasts were stimulated with
TGF-β, PDGF, or left in their baseline state. Using the
bleomycin-induced dermal ﬁbrosis mouse model, this group
also showed that imatinib treatment both prevented [12]
and decreased established cutaneous ﬁbrosis [24]. Using the
tight-skin 1 (Tsk1) murine model a similar eﬀect was shown
[13]. Similar observations were made with respect to the
eﬀects seen in cultured ﬁbroblasts and in the prevention of
skin thickening in the bleomycin mouse model with dasa-
tinib and nilotinib [13]. These well-executed studies were
essential in establishing the rationale for the clinical study of
TKIs in SSc, but it is important to note that both in vitro and
animal models of ﬁbrosis frequently fall short in predicting
clinical response in SSc.
Following this work, TKIs have been used in several
investigations delineating TGF-β signaling and its impor-
tance in the ﬁbrotic manifestations of SSc. Pannu et al.
observedthatactivationofTGF-β-mediatedSmad1signaling
occurs in a subset of SSc patients and contributes to persis-
tent activation of SSc ﬁbroblasts [25]. This Smad1 pathway is
inhibited by imatinib. Bhattacharyya et al. delineated a novel
signaling mechanism of TGF-β involving a transcription
factor called early growth response factor 1 (egr1) [26].
Recently, Bujor et al. have shown c-abl is positioned as an
upstream regulator of the pro-ﬁbrotic PKCδ/P-Fli1 pathway,
via induction of PKCδ nuclear localization [27]. Li and
Jimenez have shown that c-Abl and PKC-δ to be important
in TGF-β-induced endothelial mesenchymal transformation
[28]. These pathways are inhibited with imatinib. Addi-
tionally, microRNA29 (miR-29) has been observed to be
downregulated in SSc ﬁbroblasts, and treatment of these
ﬁbroblasts with imatinib reversed the downregulation of
miR-29a [29]. Together this body of work presents a very
compelling rationale for the investigation of these TKIs for
the treatment of ﬁbrosis in SSc and underlines the need for
well-designed clinical investigations. These studies postulate
speciﬁc biologic eﬀects which would be well tested as investi-
gationalsurrogatemarkersinaPOCstudy,andcollaboration
between labs capable of performing such investigations with
investigators performing the clinical trials needs to be a focus
of the scleroderma research community.
1.2. Treatment of Other Fibrotic Conditions with Imatinib.
Imatinib has been investigated for the treatment of vari-
ous ﬁbrotic diseases apart from systemic sclerosis. These
include nephrogenic systemic ﬁbrosis (NSF), scleroderma-
tous chronic graft-versus-host disease (cGVHD), morphea,
and idiopathic pulmonary ﬁbrosis (IPF). Kay and High
observed decreased skin thickening and reduction in the
mRSS in two patients with NSF [30]. The skin thickening
recurred upon cessation of the drug. Olivieri et al. treated
19 patients with refractory cGVHD with ﬁbrotic/sclerotic
features and reported an overall response rate at 6 months of
79%, with 7 complete remissions and 8 partial remissions
[31]. Similarly, Magro et al. reported a retrospective study
of imatinib for sclerodermatous cGVHD where 7 patients
responded, 4 of whom had mRSS improvements of 90% or
more [32]. Moinzadeh et al. reported a case of one patient
with therapy-resistant generalized morphea treated with
imatinib with improvement [33]. Imatinib was studied for
the treatment of IPF in a double-blind, placebo-controlled,
randomized trial [34]. In this study 119 patients were
treated with either imatinib or placebo at 600mg daily
(with dose adjustment to 400mg daily for perceived drug
toxicity). A diﬀerence was not detected between patients on
imatinib compared with placebo with respect to the primaryInternational Journal of Rheumatology 3
endpoint: time to disease progression as deﬁned as a 10%
decline in percent predicted forced vital capacity (FVC)
from baseline or time to death. Treatment had no eﬀect on
change in forced vital capacity or diﬀusion capacity of the
lungs for carbon monoxide (DLCO) at 48, 72, or 96 weeks.
More imatinib-treated patients discontinued study because
of perceived drug-related AEs although this did not reach
statistical signiﬁcance (imatinib: 13 versus placebo: 6; P =
0.073). These IPF results were discouraging just as the data
with sclerodermatous cGVHD and NSF seem encouraging.
In both cases, the relation to SSc is uncertain.
1.3. Safety and Tolerability from Other Patient Populations.
The side eﬀect proﬁles of tyrosine kinase inhibitors have
been described in patients with CML and other malignancies
and are summarized in a recent review by Wei et al., and in
general this is a relatively well-tolerated medication in this
patient group [35]. With respect to imatinib in CML, the
mostcommonsideeﬀectsincludemyelosuppression,nausea,
fatigue, diarrhea, edema, and muscle cramps. Edema may
be superﬁcial and responsive to diuretics but also includes
periorbital edema, which is less responsive to diuretics.
Edema is seen less commonly with dasatinib and nilotinib
when compared with imatinib. However, pleural eﬀusion is a
more prominent side eﬀect of dasatinib treatment. Nilotinib
has been associated with higher rates of dermatologic, hep-
atic, and pancreatic toxicity when compared with imatinib,
but with lower rates of gastrointestinal intolerance, muscle
spasm, and neutropenia.
Cardiotoxicity has been reported in patients with CML
treated with imatinib, with some evidence for c-abl inhi-
bition leading to this toxicity [36]. Retrospective, clinical
experiences estimate the frequency of this to occur at a rate
of 0.5–1.1% with association noted for typical risk factors
forcardiovasculardisease including age,diabetes, and hyper-
tension [37, 38]. Patients in clinical practice with CHF are
able to continue imatinib for malignancies with careful
monitoring. In studies of patients with imatinib resistance or
intolerancetreatedwithnilotinib,suddendeathwasreported
in0.6%ofpatients,andanexpanded-accessprogramshowed
a similar rate of occurrence with concern for possible
ventricularrepolarizationabnormalitiesbecauseoftiming of
events[39].Becauseofthis,thepackagelabelingfornilotinib
requires careful EKG monitoring for QTc prolongation with
repeat EKGs one week after dose adjustments and guidelines
for dose adjustments based on QTc prolongation.
The side eﬀects described above are important in an SSc
population in particular because similar phenomena may
be seen also as manifestations of disease activity. Patients
with SSc may have occult or overt cardiac involvement with
diverse manifestations ranging from conduction abnormal-
ity to cardiomyopathy. Not only is it important to carefully
monitor for cardiac complications in SSc patients treated
with TKIs, but also attribution of these side eﬀects in open-
l a b e lt r i a l sc a nb ed i ﬃcult. It would require a placebo arm
to adequately understand if in SSc certain side eﬀects can
also be disease related. Edema, which is seen commonly with
imatinib,canbeparticularlytroublesomeinaSScpopulation
already uncomfortable with tight and thick skin. This side
eﬀect can be confounding in two ways: patients may have
edema as an inherent part of early cutaneous manifestations
of SSc which and edema can be diﬃcult to distinguish from
skin thickness and lead to an elevated measurement of the
modiﬁed Rodnan Skin Score (mRSS). Myopathy is also com-
mon in scleroderma, often with low-grade creatine kinase
(CK) elevations. Similar CK elevations have been seen in
imatinib use in populations without underlying connective
tissue disorders [40]. Attribution of myopathy, myalgias, or
even asymptomatic CK elevations in imatinib-treated pa-
tients in uncontrolled clinical trials therefore can be similarly
problematic.
Vascular issues are also an issue. PDGFR is on the peri-
cyteandstabilizesbloodvessels[41].Alternatively,PDGFhas
been implicated in the abnormal proliferation and migration
of pulmonary artery smooth muscle cells [42]. This eﬀect in
vivo needs to be carefully observed and could be postulated
to lead to either eﬃcacy or side eﬀect. Indeed, Hatano et al.
treated 5 patients with PAH (3 scleroderma-associated PAH
and2 idiopathic PAH) withimatinib (100to 200mg/day) for
24 weeks in addition to standard treatment [43]. However,
there was no signiﬁcant change in hemodynamics or exercise
capacity. DLCO improved at 12 and 24 weeks of treatment
(P<0.01 and P = 0.05), and plasma PDGF-BB levels
were signiﬁcantly decreased after 12 weeks of treatment (P =
0.04). Two patients with high plasma PDGF-BB levels had
a 15% decrease in pulmonary vascular resistance. Given the
multitude of vascular issues in SSc patients, careful obser-
v a t i o nf o rv a s c u l a re ﬀect—positive or negative—needs to be
performed carefully.
1.4. Clinical Data Summary—Systemic Sclerosis. There is a
solid preclinical rationale for the use of TKIs in SSc; however,
the clinical experience in this heterogeneous patient group is
still in its early stages. Several case reports, which we have
reviewed formerly [44], suggested the clinical beneﬁt for
imatinib treatment for the cutaneous and pulmonary mani-
festations of SSc, and three open-label clinical trials have also
beenrecentlyreported.Noneofthesewerecontrolledclinical
trials, limiting what can be said deﬁnitively about either the
safetyoreﬃcacyoftyrosinekinaseinhibitioninscleroderma.
Other studies have been presented in abstract form at scien-
tiﬁcmeetings.Inadditiontothestudiesthatwillbediscussed
below, there is an Italian study still ongoing and a French
study completed but not yet reported to our knowledge.
Thereisadditionallyonetrialinvestigatingdasatinibwhichis
completed but not yet reported and one active and recruiting
trial at our center investigating nilotinib [45].
The clinical trials reported to date are heterogeneous
in terms of patient populations included, disease duration,
imatinibdosing,andstudyduration.Diﬃcultiesininterpret-
ing such open-label proof-of-concept trials with imatinib in
scleroderma relate both to generic issues in terms of inter-
preting outcomes in a disease as heterogenous and variable
in its natural history as scleroderma, as well as some issues
more uniquely related to imatinib itself, namely the edema
that often complicates treatment which can aﬀect the mRSS.4 International Journal of Rheumatology
Our group has recently reported an open-label experi-
ence treating 30 patients with dcSSc with imatinib for one
year [46]. This was a 1-year, single-center, phase 2a, single-
arm, open-label clinical trial. Two patient subgroups were
prospectivelytargetedforenrollment:20patientswithearlier
disease (<4 years) and 10 patients with later disease (4–10
years)Themeandiseaseduration basedonthetime sincethe
ﬁrstnon-Raynaud’ssymptomattributabletoSScwas3.4±2.3
years for the entire cohort. Mean disease duration in the
earlier subgroup was 2.1±1.2 years and in the later subgroup
was 6.1 ± 1.6 years. All patients had an mRSS of at least 16,
andthemeanmRSSatbaselinewas30.3±8.7.ILD,whichwas
not a requirement for entry, was present in 53% of patients.
Concomitant administration of immunosuppressive agents
was not allowed during the course of the trial or in the
3 months prior to enrollment, but 77% of patients had
been on various other treatments for dcSSc previously. The
target dose of imatinib was 400mg/daily, but the mean dose
toleratedwas300mg/daily.24of30patientsor80%tolerated
the medication well and completed the trial. Adverse events
werecommonbutmostlyofgrade1or2.Ofnote,ﬂuidreten-
tion which was seen in 80% of patients and GI side eﬀects
were similarly common. Neither of these AEs led to dis-
continuation of imatinib, but often dose adjustment or use
of concomitant diuretics was employed. Twenty-four seri-
ous AEs were identiﬁed, the majority of which were not
attributed to imatinib but to SSc itself or to complications
from former therapies.
We observed a decrease in the mRSS by 6.6 points or
22.4% from baseline at 12 months in the 24 completers
(P = 0.001). After 3 months of treatment there was no
change in mRSS, but starting at 6 months of treatment
this change started to become evident. (Δ =− 4.5; P<
0.001 at 6 months). This degree of improvement was seen
in patients both early and late-stage diseases. In patients
with disease duration of less than 18 months, there was an
improvement in the mRSS by 29.5%, in those with disease
duration less than 4 years the mRSS declined by 20.1%,
and in those with 4 to 10 years of SSc the mRSS improved
by 27.8%. There was an improvement of 6.4% predicted
(P = 0.008) in the FVC, and the diﬀusion capacity remained
stable after 12 months of treatment. The improvement in
FVC was signiﬁcantly greater in patients without interstitial
lung disease. In patients with ILD both the FVC and DLCO
remained stable over the one-year period of treatment: the
mean change in FVC was +2.1% predicted (95% CI −2.9 to
7.0; P = 0.36) and the mean change in DLCO was +1.0%
predicted (−8.0 to 10.1; P = 0.81). High-resolution CTs of
the chest, although performed as part of standard of care
in most of our patients, were not performed as part of the
study protocol and so were not reported. The scleroderma
Health Assessment Questionnaire-Disability Index (HAQ-
DI) and the short form-36 (SF-36) physical component
remained stable over the period of treatment. The SF-36
mental component, the patient global visual analogue scale
(VAS), patient shortness of breath VAS, and pain VAS all
improved signiﬁcantly. Dermatopathological assessment
demonstrated a signiﬁcant decrease in skin thickness and
improvement in skin morphology in a subset of patients.
Histologic improvements paralleled improvements in mRSS.
Our group’s experience is the most extensive published
experience of imatinib in the treatment of dcSSc. Deﬁnitive
conclusions regarding the eﬃcacy of this imatinib for the
treatment of dcSSc cannot be made based on this work
because of the open-label design. Similarly, attribution of
AEs is less certain in this sick patient population in the
absence of a parallel placebo-controlled group. A criticism of
thistrialisthatitincludedbothearlyandlater-stagepatients,
and not only early (<2 years disease duration) diﬀuse
patients as based on the guidelines recommended by White
et al. [47]. The rationale for including later-stage patients
in this work were that the primary analysis was for safety
and that this later-stage group is still very much in need
of better treatments for ﬁbrotic manifestations of both the
skin and lung. Several facts were encouraging to us: (1)
most of our patients were able to complete the trial despite
side eﬀects; (2) the improvement in mRSS held true across
diﬀerent disease durations including those with less than 18
months since the time of their ﬁrst symptom of SSc apart
from Raynaud’s; (3) histopathology supported our clinical
observations;(4)FVCandDLCOwerestableinpatientswith
ILD.
Pope et al. presented a 6-month POC trial of imatinib in
which they found imatinib to be poorly tolerated at a dose of
200mg twice daily [48]. Patients with active dcSSc as deﬁned
by an increase in mRSS, the presence of tendon friction
rubs, or an elevated ESR were recruited. These patients had
a mean disease duration of 3.1 years (range 0.3 to 6 years.)
The trial was prematurely discontinued after enrollment of
10 patients because of concerns regarding 2 serious adverse
eﬀects—ﬂuid retention and weakness, in one patient each.
This was designed as a randomized controlled trial with a
4- to 1-randomization scheme and a planned enrollment of
20. Since the trial was terminated early, 9 subjects received
active drug and only one received placebo, undermining
the study power to compare the eﬃcacy of active treatment
versus placebo. Five patients stopped the study medication
and needed to interrupt dosage due to adverse events which
included ﬂuid retention, weakness, nausea, vomiting, chest
pain, worsening anemia, and hair loss. Four patients com-
pleted six months of active therapy. The mRSS at baseline
was32.3andat6monthswas30.5,whichwasnotstatistically
diﬀerent. No signiﬁcant changes were noted with respect
to echocardiogram, PFTs, or other parameters at six months’
time. A number of exploratory translational studies from
plasma and skin biopsies were reported as not changing
signiﬁcantly from 0 to 6 months other than sVCAM in
plasma and sICAM-1 in skin, but data were not provided. An
editorial pointed out that these inclusion criteria were some-
what unusual as well as the issue with using this medication
in patients with myopathy [49]. This trial allowed concomi-
tant use of methotrexate, which can have pharmacologic
interaction with imatinib [50]. In summary, the short dura-
tion of the trial and small number of completers make the
study inconclusive with respect to eﬃcacy. This group found
the tolerability to be poor.International Journal of Rheumatology 5
Khanna et al. also reported on the use of a higher dose of
imatinib (up to 600mg daily with a mean dose tolerated of
445mg) in 20 patients with SSc-ILD (14 dcSSc and 6 lcSSc)
with treatment duration of 1 year [51]. Twelve of 20 patients
discontinued treatment: 7 due to adverse events and 1 was
lost to followup. Common AEs (≥20%) included fatigue,
edema, nausea, diarrhea, and rash. Proteinuria of a range of
81 to 402mg/dL was seen in 6 patients without concomitant
increase in creatinine. These AEs are described in detail in
this study. Adverse eﬀects were felt to be dose related. The
authors note that early in the study the ﬁrst ﬁve patients who
escalated their dose to 600mg discontinued the study. The
authors later allowed de-escalation or dose stabilization, and
in the group that maximally titrated only to 400mg/daily
there were no discontinuations. Treatment with imatinib led
to a nonstatistically signiﬁcant increase in estimated FVC %
predicted by 1.74%, TLC % predicted by 4.17%, and DLCO
% predicted by 1.46% over 1 year (P>0.05 for all). The
mRSS improved by 3.9 units (P<0.001). It is probable that
thehighlevelofadverseeventsnotedinthistrialrelatestothe
increased dose, and only 30% of patients were able to reach
that high of a dose. The improvements in indices of pul-
monary function were modest but are worth comparing in
magnitude to what was seen in the Scleroderma Lung Study
where patients had very similar inclusion criteria where
the FVC% predicted decreased by 1% point in the cyclo-
phosphamide-treated arm [52]. Attributing this change to
drug eﬀect versus natural history is not possible without a
control group, but as an exploratory POC trial this might be
considered to justify further investigation in a randomized
controlled trial.
Chung et al. reported in an interim fashion on nine
patients treated with lower-dose imatinib at 100 to 200mg
daily [53]. Their cohort included 2 patients with limited SSc
with ILD and 7 patients with diﬀuse SSc. The initial treat-
ment period was 24 weeks. During this time 7 patients were
able to complete the course of therapy, 1 patient dropped
out secondary to SSc-related keratopathy, and 1 patient with
severe ILD died from pneumonia and sepsis. Descriptive
reporting of adverse eﬀects included gastrointestinal com-
plaints, edema, and infections. An improvement in mRSS
of 32% was recognized in those patients with the diﬀuse
subtype, P = 0.005. Evaluation of changes in gene expres-
sion by microarray showed a variable cutaneous molecular
response to imatinib which might correspond to drug ef-
ﬁcacy. This group had previously reported on 2 patients
treated with imatinib 200mg/d with signiﬁcant improve-
ment in pulmonary and cutaneous parameters [54]. Skin
biopsies from these patients before and after treatment
demonstrated decreased phosphorylation of PDGF receptor
and Abl. Gene expression analysis with microarray on RNA
extracted from the skin before and after treatment described
the diﬀerential expression of 1,050 genes, which led to the
hypothesis that there may be an imatinib-responsive gene
signatureinaspeciﬁcsubgroupofpatientswithSSc.Welook
forward to ﬁnal publication of this experience. This work
not only adds to the above experience with imatinib but
raises the bigger questions of whether drug therapy inﬂu-
ences gene expression in skin and whether we can use gene
expressionanalysiswithDNAmicroarraytopredictresponse
to treatment. It is important to emphasize that it will not
necessarily completely answer these questions, but instead
willprovideinformationwhichcanbeconsideredhypothesis
generating.
Distler et al. reported the results of an industry-
sponsored multicenter study which recruited 27 patients to
be treated with imatinib initially 200mg daily to be titrated
up to 600mg daily for six months, then to be observed for
an additional 24 weeks of study therapy. This was a more
homogenous patient population with respect to disease
duration and only patients with dcSSc with less than 18
months since the ﬁrst non-Raynaud’s symptom were en-
rolled. Only 16 of 27 patients completed 24 weeks of study,
and13completedtheir48-weekstudyvisit.Theinvestigators
prospectively deﬁned a 25% decrease in mean mRSS at 24
weeks as a positive “proof of concept.” This outcome was
not met, and indeed at 24 weeks the mean mRSS increased
by 9.9%. At 48 weeks, mRSS was recognized as decreasing
by 21%. Levels of collagen Ia1 and ﬁbronectin in skin were
reducedwiththerapy,whichmightbeseenasapositiveeﬀect
on SSc biomarkers. We hope to see in the future publication
of this paper a more extensive treatment of the biological
samples obtained. The study utilized a high dose of imatinib,
and the ﬂuid retention and edema seen with this medication
which is often dose related likely could have confounded
interpretation of skin scores leading to an overestimate of
skin scores related to edema rather than true skin ﬁbrosis.
Although the results at 48 weeks demonstrated decline in
skinscore,thatwasasmallsubgroupofpatients,andinthose
ensuing several months other therapies were permitted mak-
ing it diﬃcult to know whether the improvement at 48 weeks
was related to the earlier imatinib therapy, natural history
disease, or eﬀects of other medications. Moreover, with such
substantial loss to follow up other patients, it is hard to say
whether these results are biased by the greater likelihood of
followup in patients who were doing well after exposure to
the study intervention.
Denton et al. performed a retrospective exploratory
analysisusingthese27patientsfrommultiplecentersascases
compared with well-characterized historical controls from a
single-center database matched for age, sex, duration of dis-
ease, and baseline mRSS [55] .T h ec h a n g ei nm R S So b s e r v e d
in Distler et al. was not noted to be diﬀerent from patients
treatedwithvariousstandardtreatments,whichinthisgroup
meant various active immunomodulatory agents including
cyclophosphamide and mycophenolate mofetil treatments
in 84% of the controls and no treatment in 16%. How to
interpret this comparison is diﬃcult, and there are obvious
methodologic diﬃculties with the use of historical controls.
Lumping both active treatments with immunomodulatory
regimens with no treatment makes interpretation murky,
and it is diﬃcult to draw conclusions.
The authors of the above studies reach diﬀerent con-
clusions regarding both tolerability and potential eﬃcacy of
imatinib. Some explanations for these diverse conclusions
relate to the diﬀerent populations studied: patients had dif-
ferent subsets of SSc with diﬀerent organ manifestations,
patients had diﬀerent durations of disease, diﬀerent dosages6 International Journal of Rheumatology
of imatinib were used (in our experience, adverse events, in
particular ﬂuid retention, seemed to be dose related, with
lower doses of the drug much better tolerated), and diﬀerent
durations of treatment were studied. Moreover, edema can
confound the calculation of mRSS which may have been a
consideration in the interpretation of the worsening of skin
scores at 6 months in Distler et al. in which a high dose
(600mg daily) of imatinib was used. Additionally, it has
been recently observed in a pooled analysis of 3 large RCTS
that mRSS tends to improve after entering the clinical trials
irrespective of the SSc disease duration [56].
2. Discussion
Ther eisastr ongrationalefortheuseofTKI sinSScpr o vided
by the preclinical work. The early clinical work shows
considerable adverse eﬀects but potential eﬃcacy in at least
3 of 5 the above-discussed trials. Deﬁnitive clinical inves-
tigation as from a well-designed randomized controlled-
trial is yet to be done.
With respect to clinical outcomes, there is great diﬃculty
in the interpretation of these pilot or proof-of-concept trials
dueto severalfactors.First andforemost,neither eﬃcacynor
safety can be established with certainty from an uncontrolled
experience. With respect to adverse eﬀects, many of the
symptoms attributed to medication side eﬀects can also be
attributed to the diverse manifestations of SSc, and without
a placebo arm, it is not possible to truly interpret this.
Secondly, the heterogeneous nature of dcSSc with respect to
natural course of the disease further limits these studies’
abilitytodetermineeﬃcacyespeciallyiftheeﬀectsizeissmall
or moderate. If the response to treatment were comparable
in magnitude, for example, to the eﬀects of steroids on
polymyalgia rheumatica, such conclusions would be clearer.
However,evenamodestclinicaleﬀectwouldstillbewelcome
in the treatment of systemic sclerosis and is quite diﬃcult
to judge in an uncontrolled study. Additionally given the
heterogenousnatureofthedisease,itispossiblethataclinical
eﬀect would only be seen in a subset of patients, and such a
hypothesis is put forth by the work of Chung et al.
Should open-label POC studies be performed in SSc?
It is our opinion that there is value in these pilot studies.
They aﬀord initial data on safety in a population which may
be very diﬀerent from the original population tested. With
respect to magnitude of response, this early data can be
used to develop power calculations for larger, more deﬁnitive
studies. When coupled to well-designed translational inves-
tigations these projects can illustrate important mechanistic
concepts. Additionally an open-label trial with all patients
receiving active treatment is substantially easier to recruit.
Although the POC trials have value, they are inconclusive
and speciﬁcally challenging in SSc for the reasons discussed
above. For exploration of antiﬁbrotic eﬀect, it is unlikely for
this to be observed in a short period of time given the half
life of collagen, and this type of trial is usually performed
over a short period of time. Additionally, there is a paucity
of validated surrogate endpoints or biomarkers which can
be used in SSc. In the work described above as well as in
other early pilot studies in SSc, translational investigations
are frequently utilized to explore potential mechanisms of
action or to develop new biomarkers fordisease activity. This
type of work can be considered more hypothesis-generating
mechanistic data rather than “proof-of-concept” of a clinical
eﬀect at this point in time.
Ultimately, these Proof-of-Concept open-label trials are
inadequate to deﬁnitively address eﬃcacy, safety, or even
tolerability of TKIs in scleroderma. Those determinations
will require the conduct of randomized, double-blinded,
placebo-controlled trials. With respect to the use of TKIs in
SSc, the available data, although imperfect, suggest that such
studies are worth pursuing.
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